Page last updated: 2024-11-11

linoleylanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

linoleylanilide: RN given refers to (Z,Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

linoleylanilide : A fatty amide conjugate of linoleic acid and aniline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6437086
CHEMBL ID4762255
CHEBI ID53722
SCHEMBL ID18240159
MeSH IDM0117728

Synonyms (27)

Synonym
19878-10-5
n-phenyllinoleamide
n-phenyl-9z,12z-octadecadienamide
linoleyl anilide
brn 3152993
linoleic acid anilide
linoleanilide
(z,z)-n-phenyl-9,12-octadecadienamide
9,12-octadecadienamide, n-phenyl-, (z,z)-
linoleylanilide
linoleoylanilide
CHEBI:53722
linoleic anilide
all-cis-9,12-octadecadienoic acid anilide
(9z,12z)-n-phenyloctadeca-9,12-dienamide
cis-9,cis-12-octadecadienoic acid anilide
alpha-linoleic acid anilide
(9z,12z)-n-phenyl-9,12-octadecadienamide
cis-delta9,12-octadecadienoic acid anilide
cis,cis-linoleic acid anilide
cis,cis-9,12-octadecadienoic acid anilide
4-12-00-00416 (beilstein handbook reference)
SCHEMBL18240159
Q27124175
DTXSID501314819
CHEMBL4762255
AKOS040752588

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This activity level coincided with the AchE level observed at the onset of signs in animals dosed with OPs."( Study of delayed neurotoxicity caused by fatty acid anilides in hens.
Blasco, R; Moreno, E; Repetto, M; Sanz, P, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
anilideAny aromatic amide obtained by acylation of aniline.
fatty amideA monocarboxylic acid amide derived from a fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1695710Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10
Synthesis and biological screening of a library of macamides as TNF-α inhibitors.
AID1695711Inhibition of LPS-induced TNFalpha production in human THP-1 cells incubated for 2 hrs followed by LPS stimulation and measured after 12 hrs by ELISA2020RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10
Synthesis and biological screening of a library of macamides as TNF-α inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (16.67)18.7374
1990's19 (79.17)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.67 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]